Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 7/20 | 0.47 |
| ▸ | BRD9 | Q9H8M2 | 5/20 | 0.47 |
| ▸ | BPTF | Q12830 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | NMT1 | P30419 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4292263 | 0.78 | NPC1 (0.50) | KAT2BBRD9BPTFALDH1A1MTOR | |
| SCHEMBL979278 | 0.78 | KAT2B (0.60) | KAT2BBRD9BPTFALDH1A1HPGD | |
| SCHEMBL2642056 | 0.77 | KAT2B (0.53) | KAT2BBRD9BPTFALDH1A1HPGD | |
| SCHEMBL8544499 | 0.77 | BRD9 (0.48) | KAT2BBRD9BPTFALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL17912386 | 0.77 | KAT2B (0.58) | KAT2BBRD9BPTFALDH1A1HPGD | |
| SCHEMBL17912364 | 0.75 | KAT2B (0.56) | KAT2BBRD9BPTFALDH1A1BRD4 | |
| SCHEMBL23318253 | 0.75 | KAT2B (0.43) | KAT2BBRD9BPTFALDH1A1MTOR | |
| SCHEMBL4163687 | 0.75 | KAT2B (0.47) | KAT2BBRD9BPTFALDH1A1HPGD | |
| SCHEMBL8281635 | 0.75 | MTOR (0.43) | KAT2BBRD9BPTFALDH1A1MTOR | |
| SCHEMBL2642058 | 0.75 | KAT2B (0.47) | KAT2BBRD9BPTFALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| CN-107406429-B | Pyridazinone derivatives and their use in the treatment of cancer | 基因泰克公司 | 2021-07-06 | — | — | CN | disclosed |
| US-10239861-B2 | Therapeutic compounds and uses thereof | GENETECH, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10239861-B2 | Therapeutic compounds and uses thereof | GENETECH, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-3242874-B1 | PYRIDAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | GENENTECH INC (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-02-08 | — | — | US | disclosed |
| EP-3242874-A1 | PYRIDAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2017-11-15 | — | — | EP | disclosed |
| WO-2016112298-A1 | PYRIDAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2016-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239861-B2 | Therapeutic compounds and uses thereof | HDAC10, HDAC6, HDAC11 | KAT2B 103/4885BRD9 2896/4885BPTF 20/4885 |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | HDAC10, HDAC6, HDAC11 | KAT2B 103/4885BRD9 2896/4885BPTF 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.